Robert Kawasaki, MD
Physical Medicine & Rehabilitation · Denver, CONPI 1942231303
Payments from drug & device makers
Across 24 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$138
- Amgen$103
- Scilex Pharmaceuticals Inc.$73
- Ultragenyx Pharmaceutical Inc.$36
- Daiichi Sankyo Inc.$25
- Johnson & Johnson$22
- plus $139 from 9 others
What the payments were for
- Food & beverage$536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $138 |
| Amgen | 4 | $103 |
| Scilex Pharmaceuticals Inc. | 4 | $73 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Shionogi Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| MDD US Operations, LLC | 1 | $17 |
| Bioventus LLC | 1 | $17 |
| Pfizer | 1 | $15 |
| Baudax Bio Inc. | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| AstraZeneca | 1 | $12 |
| Collegium Pharmaceutical, Inc. | 1 | $11 |
How this compares
$536 in reported general payments places this provider in the 65th percentile of 199 physical medicine & rehabilitation providers in Colorado.
See all physical medicine & rehabilitation providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 71 | $1,822 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 55 | $1,739 |
| Morphine Sulfate ErMorphine Sulfate | 46 | $1,197 |
| Oxycodone Hcl | 47 | $877 |
| Tizanidine Hcl | 45 | $580 |
| Fentanyl | 11 | $576 |
| Tramadol Hcl | 46 | $507 |
| Gabapentin | 37 | $473 |
| Ibuprofen | 17 | $187 |
| Trazodone Hcl | 27 | $129 |
| Celecoxib | 13 | $118 |
| Cyclobenzaprine Hcl | 19 | $56 |
| Meloxicam | 17 | $35 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Denver
- Gin-Ming HsuDenver$8K
- Yusuke WakeshimaDenver$5K
- Mara Isser SaxDenver$3K
- Usama GhaziDenver$2K
- Yani ZinisDenver$713
- Drew TrainorGreenwood Village$1.8M
- Kenneth WashburnGrand Junction$77K
- William ScelzaEnglewood$16K
- Aakash ThakralGreeley$14K
- Jeffrey BerlinerEnglewood$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.